Page 154 - Cardiac Nursing

g
P
M
e 1
31.
qxd
0
009
30
p11
8:2
5 A
9/0
9/2
K34
0-c
05_
L L LWB K34 0-c 05_ p11 1-1 31. qxd 0 9/0 9/2 009 0 0 8:2 5 A M P a a g e 1 30 Apt ara
LWBK340-c05_p111-131.qxd 09/09/2009 08:25 AM Page 130 Aptara
LWB
ara
1-1
Apt
130 PA R T I I / Physiologic and Pathologic Responses
172. Liuzzo, G., Biasucci, L. M., Gallimore, J. R., et al. (1994). The prog- 195. Hardardottir, I., Moser, A. H., Memon, R., et al. (1994). Effects of TNF,
nostic value of C-reactive protein and serum amyloid a protein in severe IL-1, and the combination of both cytokines on cholesterol metabolism
unstable angina. New England Journal of Medicine, 331, 417–424. in Syrian hamsters. Lymphokine & Cytokine Research, 13, 161–166.
173. Sacks, F. M., Pfeffer, M. A., Moye, L. A., et al. (1996). The effect of 196. van der Poll, T., van Deventer, S. J., Pasterkamp, G., et al. (1992). Tu-
pravastatin on coronary events after myocardial infarction in patients mor necrosis factor induces von Willebrand factor release in healthy hu-
7
7
with average cholesterol levels. Cholesterol and Recurrent Events Trial mans. Thrombosis and Haemostasis, 67, 623–626.
investigators. New England Journal of Medicine, 335, 1001–1009. 197. Yudkin, J. S., Kumari, M., Humphries, S. E., et al. (2000). Inflamma-
174. Pearson, T. A., Mensah, G. A., Alexander, R. W., et al. (2003). Markers tion, obesity, stress and coronary heart disease: Is interleukin-6 the link?
of inflammation and cardiovascular disease: Application to clinical and Atherosclerosis, 148, 209–214.
public health practice: A statement for healthcare professionals from the 198. Ridker, P. M., Rifai, N., Stampfer, M. J., et al. (2000). Plasma concen-
Centers for Disease Control and Prevention and the American Heart As- tration of interleukin-6 and the risk of future myocardial infarction
sociation. Circulation, 107, 499–511. among apparently healthy men. Circulation, 101, 1767–1772.
7
7
175. Folsom, A. R., Pankow, J. S., Tracy, R. P., et al. (2001). Association of 199. Volpato, S., Guralnik, J. M., Ferrucci, L., et al. (2001). Cardiovascular
C-reactive protein with markers of prevalent atherosclerotic disease. disease, interleukin-6, and risk of mortality in older women: The
American Journal of Cardiology, 88, 112–117. women’s health and aging study. Circulation, 103, 947–953.
176. Yu, H., & Rifai, N. (2000). High-sensitivity C-reactive protein and ath- 200. Harris, T. B., Ferrucci, L., Tracy, R. P., et al. (1999). Associations of ele-
erosclerosis: From theory to therapy. Clinical Biochemistry, 33, 601–610. vated interleukin-6 and C-reactive protein levels with mortality in the
177. McCully, K. S. (1969). Vascular pathology of homocysteinemia: Impli- elderly. American Journal of Medicine, 106, 506–512.
6
6
cations for the pathogenesis of arteriosclerosis. American Journal of 201. Mendall, M. A., Patel, P., Asante, M., et al. (1997). Relation of serum
Pathology, 56, 111–128. cytokine concentrations to cardiovascular risk factors and coronary heart
6
6
178. Boushey, C. J., Beresford, S. A., Omenn, G. S., et al. (1995). A quanti- disease. Heart, 78, 273–277.
tative assessment of plasma homocysteine as a risk factor for vascular dis- 202. Biasucci, L. M., Vitelli, A., Liuzzo, G., et al. (1996). Elevated levels of
4
ease. Probable benefits of increasing folic acid intakes. Journal of the interleukin-6 in unstable angina. Circulation, 94, 874–877.
4
American Medical Association, 274, 1049–1057. 203. Biasucci, L. M., Liuzzo, G., Fantuzzi, G., et al. (1999). Increasing levels
4
4
179. Christen, W. G., Ajani, U. A., Glynn, R. J., et al. (2000). Blood levels of of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitaliza-
homocysteine and increased risks of cardiovascular disease: Causal or ca- tion in unstable angina are associated with increased risk of in-hospital
sual? Archives of Internal Medicine, 160, 422–434. coronary events. Circulation, 99, 2079–2084.
180. Tsai, J. C., Perrella, M. A., Yoshizumi, M., et al. (1994). Promotion of 204. Biasucci, L. M., Liuzzo, G., Grillo, R. L., et al. (1999). Elevated levels of
vascular smooth muscle cell growth by homocysteine: A link to athero- C-reactive protein at discharge in patients with unstable angina predict
sclerosis. Proceedings of the National Academy of Sciences USA, 91, recurrent instability. Circulation, 99, 855–860.
6369–6373. 205. Malle, E., & De Beer, F. C. (1996). Human serum amyloid A (SAA)
181. El-Khairy, L., Ueland, P. M., Nygard, O., et al. (1999). Lifestyle and car- protein: A prominent acute-phase reactant for clinical practice. European
diovascular disease risk factors as determinants of total cysteine in Journal of Clinical Investigations, 26, 427–435.
6
6
plasma: The Hordaland Homocysteine Study. American Journal of Clin- 206. Benditt, E. P., Lagunoff, D., Eriksen, N., et al. (1962). Amyloid. Ex-
ical Nutrition, 70, 1016–1024. traction and preliminary characterization of some proteins. Archives of
4
4
182. Lowering blood homocysteine with folic acid based supplements: Meta- Pathology, 74, 323–330.
analysis of randomised trials. Homocysteine Lowering Trialists’ Collab- 207. Gabay, C., & Kushner, I. (1999). Acute-phase proteins and other systemic re-
0
6
6
oration. (1998). BMJ, 316, 894–898. sponses to inflammation. New England Journal of Medicine, 340, 448–454.
183. Eikelboom, J. W., Lonn, E., Genest, J., Jr., et al. (1999). Homocyst(e)ine 208. Banka, C. L., Yuan, T., de Beer, M. C., et al. (1995). Serum amyloid A
and cardiovascular disease: A critical review of the epidemiologic evidence. (SAA): Influence on HDL-mediated cellular cholesterol efflux. Journal
Annals of Internal Medicine, 131, 363–375. Lipid Research, 36, 1058–1065.
6
6
184. Shipchandler, M. T., & Moore, E. G. (1995). Rapid, fully automated 209. Yamada, T., Kakihara, T., Kamishima, T., et al. (1996). Both acute phase
measurement of plasma homocyst(e)ine with the Abbott IMx analyzer. and constitutive serum amyloid A are present in atherosclerotic lesions.
6
6
Clinical Chemistry, 41, 991–994. Pathology International, 46, 797–800.
185. Zighetti, M. L., Chantarangkul, V., Tripodi, A., et al. (2002). Determi- 210. Kisilevsky, R., & Subrahmanyan, L. (1992). Serum amyloid A changes
nation of total homocysteine in plasma: Comparison of the Abbott IMx high density lipoprotein’s cellular affinity. A clue to serum amyloid A’s
6
6
immunoassay with high performance liquid chromatography. Haemato- principal function. Laboratory Investment, 66, 778–785.
7
7
logica, 87, 89–94. 211. Coetzee, G. A., Strachan, A. F., van der Westhuyzen, D. R., et al. (1986).
186. Van Snick, J. (1990). Interleukin-6: An overview. Annual Review of Im- Serum amyloid A-containing human high density lipoprotein 3. Den-
munology, 8, 253–278. sity, size, and apolipoprotein composition. Journal of Biology and Chem-
187. Baumann, H., & Gauldie, J. (1990). Regulation of hepatic acute phase istry, 261, 9644–9651.
plasma protein genes by hepatocyte stimulating factors and other medi- 212. Steinmetz, A., Hocke, G., Saile, R., et al. (1989). Influence of serum
ators of inflammation. Molecular Biology/Medicine, 7, 147–159. amyloid A on cholesterol esterification in human plasma. Biochimica
7
7
6
188. Mestries, J. C., Kruithof, E. K., Gascon, M. P., et al. (1994). In vivo mod- Biophysica Acta, 1006, 173–178.
6
ulation of coagulation and fibrinolysis by recombinant glycosylated human 213. Brinckerhoff, C. E., Mitchell, T. I., Karmilowicz, M. J., et al. (1989).
interleukin-6 in baboons. European Cytokine Network, 5, 275–281. Autocrine induction of collagenase by serum amyloid A-like and beta 2-
189. Loppnow, H., & Libby, P. (1989). Adult human vascular endothelial microglobulin-like proteins. Science, 243, 655–657.
cells express the IL6 gene differentially in response to LPS or IL1. Cell 214. Migita, K., Kawabe, Y., Tominagam, M., et al. (1998). Serum amyloid
Immunology, 122, 493–503. A protein induces production of matrix metalloproteinases by human
190. Loppnow, H., & Libby, P. (1989). Comparative analysis of cytokine in- synovial fibroblasts. Laboratory Investment, 78, 535–539.
duction in human vascular endothelial and smooth muscle cells. Lym- 215. Shainkin-Kestenbaum, R., Zimlichman, S., Lis, M., et al. (1996). Mod-
phokine Research, 8, 293–299. ulation of prostaglandin I2 production from bovine aortic endothelial
191. Rus, H. G., Vlaicu, R., & Niculescu, F. (1996). Interleukin-6 and inter- cells by serum amyloid A and its N-terminal tetradecapeptide. Biomed-
leukin-8 protein and gene expression in human arterial atherosclerotic ical Peptides, Proteins and Nucleic Acids, 2, 101–106.
wall. Atherosclerosis, 127, 263–271. 216. Syversen, P. V., Saeter, U., Cunha-Ribeiro, L., et al. (1994). The effect of
7
7
192. Herity, N. A. (2000). Interleukin 6: A message from the heart. Heart, serum amyloid protein A fragment-SAA25-76 on blood platelet aggre-
4
4
6
84, 9–10. gation. Thrombosis Research, 76, 299–305.
6
193. Mohamed-Ali, V., Goodrick, S., Rawesh, A., et al. (1997). Subcutaneous 217. Zimlichman, S., Danon, A., Nathan, I., et al. (1990). Serum amyloid A,
adipose tissue releases interleukin-6, but not tumor necrosis factor-al- an acute phase protein, inhibits platelet activation. Journal of Laboratory
6
pha, in vivo. Journal of Clinical Endocrinology & Metabolism, 82, and Clinical Medicine, 116, 180–186.
6
4196–4200. 218. Cushman, M., Lemaitre, R. N., Kuller, L. H., et al. (1999). Fibrinolytic
194. Hotamisligil, G. S., Murray, D. L., Choy, L. N., et al. (1994). Tumor activation markers predict myocardial infarction in the elderly. The Car-
necrosis factor alpha inhibits signaling from the insulin receptor. Pro- diovascular Health Study. Arteriosclerosis, Thrombosis, and Vascular Biology,
ceedings of the National Academy of Sciences USA, 91, 4854–4858. 19, 493–498.